Bank of America assumed coverage on shares of Fulcrum Therapeutics (NASDAQ:FULC) in a research report report published on Monday morning, 24/7 WallStreet reports. The brokerage issued a buy rating and a $19.00 price target on the stock.
NASDAQ:FULC opened at $9.26 on Monday. Fulcrum Therapeutics has a fifty-two week low of $9.25 and a fifty-two week high of $15.94.
In other Fulcrum Therapeutics news, Director Mark J. Levin bought 81,250 shares of the stock in a transaction on Monday, July 22nd. The shares were bought at an average price of $16.00 per share, with a total value of $1,300,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Also, major shareholder 6 Dimensions Capital, L.P. bought 118,750 shares of the stock in a transaction on Monday, July 22nd. The shares were acquired at an average cost of $16.00 per share, for a total transaction of $1,900,000.00. The disclosure for this purchase can be found here.
Fulcrum Therapeutics Company Profile
Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that are developing for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-HbF, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and b-thalassemia.
Featured Article: What Are Cryptocurrencies?
Receive News & Ratings for Fulcrum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulcrum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.